Cargando…

EPA guidance on treatment of cognitive impairment in schizophrenia

ABSTRACT: Although cognitive impairment is a core symptom of schizophrenia related to poore outcome in different functional domains, it still remains a major therapeutic challenge. To date, no comprehensive treatment guidelines for cognitive impairment in schizophrenia are implemented. The aim of th...

Descripción completa

Detalles Bibliográficos
Autor principal:	Vita, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417862/ http://dx.doi.org/10.1192/j.eurpsy.2023.124

Ejemplares similares

Treatment of Cognitive Impairment in Schizophrenia
por: Vita, A.
Publicado: (2022)

EPA guidance on treatment of negative symptoms in schizophrenia
por: Galderisi, S., et al.
Publicado: (2021)

EPA guidance on assessment of negative symptoms in schizophrenia
por: Galderisi, S., et al.
Publicado: (2021)

EPA in schizophrenia and violence
por: Treasaden, Ian H
Publicado: (2010)

European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
por: Vita, Antonio, et al.
Publicado: (2022)

European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia
por: Vita, Antonio, et al.
Publicado: (2022)

Recognition and Assessment of Cognitive Impairment in Schizophrenia
por: Mucci, A., et al.
Publicado: (2022)

Discussion on Assessment and Treatment of Cognitive Impairment and New Developments of Cognitive Remediation in Schizophrenia
por: Wykes, T.
Publicado: (2022)

Cannabis use and cognitive impairment in schizophrenia
por: Gonçalves, M., et al.
Publicado: (2022)

Cognitive impairment in treatment-refractory schizophrenia and type i diabetes. A case
por: Rodriguez, L. Soldado, et al.
Publicado: (2021)

Effectiveness of cognitive remediation in schizophrenia: What works and what does not work?
por: Vita, A., et al.
Publicado: (2021)

REVIEW OF WORKPLACE-RELATED GUIDANCE PRESENTED BY ORGANIZATIONS DEALING WITH DEMENTIA OR MILD COGNITIVE IMPAIRMENT
por: Carino, James, et al.
Publicado: (2022)

The pharmacotherapy of depression with EPA
por: Puri, Basant K
Publicado: (2010)

EPA 2020 Abstracts, Part 2
Publicado: (2020)

Evidences of neurodegenerative processes in patients with late-onset schizophrenia and cognitive impairment
por: Pochueva, V., et al.
Publicado: (2022)

Alcohol related cognitive impairments in schizophrenia patients : A case-control study
por: Angerville, B., et al.
Publicado: (2023)

Antipsychotic treatment and cognitive function in patients with schizophrenia
por: Tumova, M. A., et al.
Publicado: (2023)

EPA and Huntington's chorea: treatment and associated cerebral changes
por: Puri, Basant K
Publicado: (2010)

Negative and Cognitive Symptoms of Schizophrenia: Are there Adequate Pharmacological Treatments?
por: Vasiliu, O.
Publicado: (2022)

Impairment of motivation in patients with schizophrenia and the development of a program for their psychosocial treatment
por: Mitikhin, V., et al.
Publicado: (2021)

F231. GYM RATS: EXERCISE REVERSES COGNITIVE IMPAIRMENT IN THE PHENCYCLIDINE RAT MODEL OF SCHIZOPHRENIA
por: Heaney, Lisa, et al.
Publicado: (2018)

Https://cpaper.ctimeetingtech.com/epa21/submission/edit
por: Alonzo, D.
Publicado: (2021)

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
por: McCutcheon, Robert A., et al.
Publicado: (2023)

Interrelation of visual and olfactory impairments in schizophrenia
por: Tumova, M., et al.
Publicado: (2021)

Impaired age self-consciousness in latent schizophrenia
por: Suleimanov, R., et al.
Publicado: (2021)

Factors affecting cognitive remediation outcome in schizophrenia: The role of treatment resistance
por: Spangaro, M., et al.
Publicado: (2021)

PM505. Impaired glucose tolerance, symptoms and cognitive deficits in first-episode drug-naïve patients with schizophrenia
por: Zhang, Xiang-Yang, et al.
Publicado: (2016)

The structure, biosynthesis and functions of EPA: biomolecular neuropsychiatric aspects
por: Tsaluchidu, Sofia
Publicado: (2010)

Cognitive behavioral therapy for patients with schizophrenia
por: Binic, I., et al.
Publicado: (2023)

Introduction to treatment guidance
por: Sartorius, Norman
Publicado: (2010)

cognitive complaints in schizophrenia: characteristics and relationship with insight
por: Bouhamed, M., et al.
Publicado: (2022)

Interactions between dopamine transporter and N-methyl-D-aspartate receptor-related amino acids on cognitive impairments in schizophrenia
por: Chou, Y.-H.
Publicado: (2023)

S98. THE RELATIONSHIP BETWEEN CARDIOVASCULAR RISK FACTORS AND COGNITIVE IMPAIRMENT IN PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2018)

S53. COMPARISON OF RALOXIFENE AND ISRADIPINE AS AN ADJUNCTIVE TREATMENT IN COGNITIVE DEFICITS OF PATIENTS WITH SCHIZOPHRENIA
por: Vahdani, Bita, et al.
Publicado: (2018)

A polydiagnostic approach to cognitive deficits in schizophrenia
por: Sánchez-Torres, A., et al.
Publicado: (2021)

25. OLIGODENDROCYTE-BASED IMPAIRMENT OF BRAIN CONNECTIVITY AS TARGET FOR NEW TREATMENT STRATEGIES IN SCHIZOPHRENIA
por: Steiner, Johann
Publicado: (2018)

Correction: Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
por: McCutcheon, Robert A., et al.
Publicado: (2023)

Psychiatry training goes virtual: the experience of the first online edition of the EPA Research Summer School
por: De Filippis, R., et al.
Publicado: (2022)

T169. COGNITIVE INSIGHT AND CORTICAL THICKNESS IN SCHIZOPHRENIA
por: Jacob, Arpitha, et al.
Publicado: (2018)

The factors associated with subjective cognitive complaints in schizophrenia
por: Bouhamed, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t3j405jgocpblrfc2mdf3bc11s